BioStem Technologies, Inc.

NASDAQ:BSEM

Biotechnology

Healthcare
$3.07 -6.54%

-$0.21 today

Market cap
$52.14M
Beta
0.26
P/E (TTM)
-1.8
EPS (TTM)
-$1.63
52W Low $2.25High $8.40

Volume 0.09M

Average 0.07M

Returns on capital

BioStem Technologies, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-16.8%

avg 89.5%

ROIC

-1.6%

avg 2032.4%

ROA

-13.2%

avg -98.0%

Analysis

ROIC is currently the strongest return metric at -1.6% versus its period average of 2032.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jason Matuszewski

Chief Executive Officer, President, Secretary & ChairmanUSD 900K3999.90K0.59%

Andrew Vanvurst

Chief Operating Officer & DirectorUSD 630K34——

Michael Fortunato

Chief Accounting OfficerUSD 506.25K58——

Brandon Poe

Chief Financial OfficerUSD 330.43K566.78K0.04%

Barry J. Hassett

Chief Commercial Officer—59——

Noah Agron

Vice President of Corporate Finance & Strategy————

Katherine Gorrell

Chief Legal & Compliance Officer—490<0.01%

David Woynarowski

Chief Medical Officer————

Jeff Humke

Vice President of Human Resources————

Larry Jones

Chief Revenue Officer————

Irmgard Huber

International Medical Advisor & Interim Chief Medical Officer————

Compensation is shown in the reported currency; data updated Sep 19, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 17, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+90.4%
+19.2% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at +90.4% over three years. Forward estimates point to Revenue at +19.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does BioStem Technologies, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

No competitor data available.

Questions

Management questions

Common questions about BSEM's management, answered from reported figures.

Who manages BSEM?

BioStem Technologies, Inc. (BSEM) lists 11 active executives. The top listed executive is Barry J. Hassett, Chief Commercial Officer.

Are BSEM insiders buying or selling?

Recent insider activity shows net buying of $0.00.